iOncologi Inc, a US-based clinical-stage biopharmaceutical company, announced on Friday that it has acquired TargImmune Therapeutics, a Swiss biotechnology company specialising in novel tumour targeted immunotherapies.

The transaction is claimed to improves iOncologi's capabilities in developing immunotherapies for solid tumours. It aligns with the company's broader strategy to expand its therapeutic pipeline, use next-generation RNA-based immunotherapies, and drive innovation in oncology.

As part of the transaction, iOncologi Inc and TargImmune Therapeutics executed a share purchase agreement, resulting in iOncologi acquiring at least 99 percent of TargImmune's shares, warrants, and options. Following the acquisition, TargImmune will continue to operate in Basel, Switzerland, as a wholly owned subsidiary of iOncologi, Inc. This structure is intended to ensures the seamless continuation of TargImmune's research into novel tumour-targeted RNA therapies, while benefiting from iOncologi's expanded resources and strategic vision.

Dr Edgardo Rodriguez-Lebron, iOncologi's recently appointed CEO, said: "This acquisition represents a pivotal moment for iOncologi as we continue to push the boundaries of immunotherapy for solid tumours. TargImmune's pioneering approaches perfectly align with our mission to develop transformative cancer therapies. By integrating two incredibly talented and highly experienced drug development teams, we are well-positioned to accelerate innovation and bring novel treatments to patients with limited therapeutic options."